公开(公告)号：US12109215B2

公开(公告)日：2024-10-08

申请号：US16644633

申请日：2018-09-07

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Jacqueline M. Mason ,  Mark R. Bray ,  Tak Wah Mak ,  Graham Fletcher

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/5377 ,  A61K39/3955 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：US20230165871A1

公开(公告)日：2023-06-01

申请号：US17917027

申请日：2021-04-05

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Graham Fletcher ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: A61K31/5377 ,  C07K16/28 ,  A61K45/06

CPC classification number: A61K31/5377 ,  A61K45/06 ,  C07K16/2827

Abstract: Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Uses of an effective amount of Compound [I] and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-linhibitor or a PD-L1 inhibitor for treating triple negative breast cancer are also provided herein.

公开(公告)号：US10239881B2

公开(公告)日：2019-03-26

申请号：US15521895

申请日：2015-10-09

Applicant: University Health Network

Inventor： Radoslaw Laufer ,  Grace Ng ,  Richard Brokx ,  Heinz W. Pauls ,  Sze-wan Li ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P37/06 ,  A61P29/00 ,  A61P35/00

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

公开(公告)号：US20230010772A1

公开(公告)日：2023-01-12

申请号：US17782632

申请日：2020-12-04

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark R. Bray ,  Jacqueline M. Mason ,  Graham Fletcher

IPC: A61K31/5377 ,  A61K31/635 ,  A61K31/706 ,  A61P35/00 ,  A61K9/00

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220089725A1

公开(公告)日：2022-03-24

申请号：US17430311

申请日：2020-02-14

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Richard Brokx ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/63

Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

公开(公告)号：US20190225617A1

公开(公告)日：2019-07-25

申请号：US16258753

申请日：2019-01-28

Applicant: University Health Network

Inventor： Radoslaw Laufer ,  Grace Ng ,  Richard Brokx ,  Heinz W. Pauls ,  Sze-Wan Li ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: C07D487/04 ,  A61P35/00 ,  A61P29/00 ,  A61K31/519 ,  A61K45/06 ,  A61P37/06

Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

公开(公告)号：US09642856B2

公开(公告)日：2017-05-09

申请号：US15029269

申请日：2014-10-03

Applicant: University Health Network

Inventor： David W. Hedley ,  Ines Lohse ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00 ,  C07D413/14 ,  A61K45/06 ,  A61K31/7068 ,  A61K33/24

CPC classification number: A61K31/5377 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  C07D403/08 ,  C07D413/14 ,  A61K2300/00

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20250049787A1

公开(公告)日：2025-02-13

申请号：US18723094

申请日：2022-12-21

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark R. Bray ,  Jacqueline M. Mason ,  Xin Wei ,  Gordon Duncan

IPC: A61K31/496 ,  A61K31/635 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230174549A1

公开(公告)日：2023-06-08

申请号：US17924220

申请日：2021-05-10

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark R. Bray ,  Sze-Wan Li

IPC: C07D495/04 ,  C07C59/255 ,  A61K45/06

CPC classification number: C07D495/04 ,  C07C59/255 ,  A61K45/06 ,  C07B2200/13

Abstract: A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed. (I), Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.

公开(公告)号：US20180282335A1

公开(公告)日：2018-10-04

申请号：US15521895

申请日：2015-10-09

Applicant: University Health Network

Inventor： Radoslaw Laufer ,  Grace Ng ,  Richard Brokx ,  Heinz W. Pauls ,  Sze-wan Li ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: C07D487/04 ,  A61P35/00 ,  A61P29/00 ,  A61P37/06

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).